Loading...
NPI 1972546737 · Honolulu, HI · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Longs Drug Stores California LLC is a community/retail pharmacy provider located in Honolulu, Hawaii. This profile covers 9 Medicare and 12 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Longs Drug Stores California LLC |
| Address | 377 Keahole St |
| City | Honolulu |
| State | HI |
| ZIP | 96825 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | June 13, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $438.7K |
| Medicaid | $26.5K |
Medicare dominates this provider’s public payer mix: lifetime Medicare revenue is $438.7K versus $26.5K in Medicaid, so Medicare activity drives the vast majority of billings and would be the primary lens for payer/provider analysts evaluating financial exposure. The Medicaid book of business is present but small in scale relative to Medicare.
The provider’s service mix is consistent with a community/retail pharmacy that focuses on immunizations and COVID testing: top Medicare codes include K1034 ($121.7K, 27.6%), 91322 ($116.5K, 26.4%) and 90694 ($53.1K, 12.0%), and these codes represent point-of-care COVID test provision and vaccine administration. Average paid-per-claim values reinforce that mix (e.g., K1034 $11 avg paid/claim, 91322 $143 avg paid/claim, 90694 $75 avg paid/claim), indicating transaction-level volume for low-dollar test items and higher unit payments for vaccine injections.
Revenue concentration on Medicare is high: the precomputed top-3 Medicare codes account for 66.0% of this provider’s total Medicare revenue, driven by K1034, 91322, and 90694. This concentration signals operational dependence on a narrow set of vaccine and COVID test services, which may amplify seasonality or policy/payment changes that affect those codes.
Medicaid revenue is also concentrated but to a lesser extent: the top-3 Medicaid codes account for 44.7% of total Medicaid revenue, with 91320 ($4.2K, 15.8%), 91322 ($3.9K, 14.6%) and 0064A ($3.8K, 14.2%) comprising the largest shares. The Medicaid mix mirrors Medicare in emphasizing COVID vaccine administration codes, though absolute Medicaid dollar volumes are modest.
Competitive standing on Medicare for the top codes shows substantial ranked activity but is characterized in the data as typical rather than anomalous: K1034 ranks #303 of 30143 providers nationally (99th percentile; typical, unremarkable volume for this code), 91322 ranks #102 of 29357 (100th percentile; typical, unremarkable volume), and 90694 ranks #295 of 51679 (99th percentile; typical, unremarkable volume). In plain terms, this provider posts high absolute ranks for these services yet the dataset classifies those volumes as within expected ranges for a retail pharmacy that offers vaccines and tests.
State-level competitive signals for Medicaid indicate a modest in-state presence rather than dominance: 91320 ranks #9 of 19 providers in-state (56th percentile; typical, unremarkable volume), 91322 ranks #21 of 32 (35th percentile; typical, unremarkable volume), and 0064A ranks #35 of 98 (65th percentile; typical, unremarkable volume). These rankings suggest other Hawaii providers post similar or greater Medicaid activity for vaccines, so this entity is a participant but not a clear statewide leader for those Medicaid codes.
The provider has long tenure in the NPI registry, enumerated on 2006-06-13 (~20 years ago), which aligns with expectations for an established retail pharmacy operation and may correspond to stable operational processes for immunization and testing services. Long enumeration supports assessments that billing patterns reflect an operational norm rather than a recent entrant’s irregular activity.
There are no codes in the provided lists labeled as outliers or flagged for atypical statistical behavior; most high-ranking codes are explicitly described as "typical, unremarkable volume for this code." Analysts should therefore interpret the profile as a high-volume but operationally conventional retail pharmacy model, while also noting the business risk associated with heavy reliance on a few vaccine/test codes that drive much of Medicare revenue.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 11,060 | $10 | $121.7K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 820 | $140 | $116.5K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 710 | $80 | $53.1K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 820 | $40 | $35.2K |
| G0008 | Administration of influenza virus vaccine | 1,100 | $30 | $34K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 120 | $280 | $32.5K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 380 | $70 | $27.3K |
| 0134A | N/A | 470 | $40 | $20.2K |
| G0009 | Administration of pneumococcal vaccine | 110 | $10 | $1K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 9 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 40 | $100 | $4.2K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 30 | $110 | $3.9K |
| 0064A | N/A | 90 | $40 | $3.8K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 340 | $10 | $3.8K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 80 | $40 | $3.1K |
| 0134A | N/A | 50 | $40 | $2K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 110 | $20 | $1.8K |
| 0012A | N/A | 40 | $40 | $1.6K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 40 | $30 | $1.1K |
| 0011A | N/A | 20 | $30 | $610 |
Showing 1–10 of 12
How this provider's Medicaid billing volume and revenue compare to other Hawaii providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Hawaii median
12 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 74 | 230 | 140 | $20 | $16.1K |
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 9 | 20 | 30 | $120 | $12.1K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 21 | 30 | 50 | $110 | $7.7K |
| 0012A | N/A | 60 | 90 | 70 | $30 | $5.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 98 | 180 | 120 | $10 | $4.7K |
| 0011A | N/A | 75 | 90 | 80 | $20 | $4.4K |
| 0064A | N/A | 35 | 100 | 60 | $30 | $3.2K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 18 | 60 | 50 | $30 | $2.8K |
| 0134A | N/A | 12 | 40 | 30 | $30 | $1.5K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 37 | 60 | 50 | $20 | $1.3K |
Showing 1–10 of 12
Other providers in the same ZIP code as Longs Drug Stores California LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Aloha Medical Supply Of The Pacific Inc., | HI | Durable Medical Equipment & Medical Supplies | $0 | $1.6M |
| Steven Ito | HI | Family Nurse Practitioner | $228.7K | $0 |
| Suzanne Aquino | HI | Diagnostic Radiology Physician | $121.3K | $18.8K |
| Walgreen Co | HI | Pharmacy | $139.1K | $110 |
| Kenneth Chang | HI | Ophthalmology Physician | $133K | $0 |
| Erin Fuller | HI | Dermatology Physician | $78.4K | $0 |
| Costco Wholesale Corporation | HI | Community/Retail Pharmacy | $75.8K | $0 |
| Jason Dacumos | HI | Specialist | $69.4K | $0 |
| Eric Yee | HI | Family Medicine Physician | $62.9K | $0 |
| Yunsim Suehisa | HI | Physical Therapist | $61.7K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.